CG Oncology, Inc. (CGON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Viewpoint - CG Oncology is focused on developing a bladder-sparing therapeutic for bladder cancer patients, targeting a market of approximately 150,000 patients annually in the U.S. [2] Company Overview - The incidence of bladder cancer in the U.S. is about 85,000 patients per year, with a prevalence exceeding 700,000 patients [3] - 75% of bladder cancer patients are classified as non-muscle invasive, which is characterized by frequent recurrences that can lead to progression and metastatic disease [3] Strategic Focus - CG Oncology is concentrating on the non-muscle invasive bladder cancer segment, specifically targeting intermediate risk and high-risk populations [4] - The company has invested in two pivotal Phase III trials, with one expected to read out results in the first half of this year [4]